Sygnature Discovery has appointed Fraser McIntosh as Vice President, In Vivo Pharmacology. Fraser will lead the company’s in vivo drug discovery operations worldwide.

Fraser brings 30 years of experience as a senior leader in drug discovery spanning the pharmaceutical, biotechnology, and contract research organization sectors. He has supported numerous programs into clinical development and fostered cross-functional collaboration across diverse therapeutic areas and drug modalities.

At Sygnature, Fraser will spearhead the in vivo pharmacology business, setting strategic direction and driving scientific and operational excellence across the company’s UK and Canada sites. He will work to identify new commercial opportunities, integrate cutting-edge methodologies, and uphold the highest ethical and regulatory standards for all in vivo projects.

Fraser said, “I am delighted to join Sygnature Discovery at such an exciting point in the company’s growth and to contribute to this next phase of development. Sygnature’s talented scientific teams have a stellar reputation for delivering drug candidates across multiple therapeutic areas. I’m eager to leverage my drug discovery experience to build a global, integrated in vivo pharmacology department that supports Sygnature’s vision of becoming the leading global drug discovery CRO.”

Dr Simon Hirst, CEO of Sygnature Discovery, added, “Fraser’s expertise in leading in vivo pharmacology operations globally is a tremendous asset as we expand our customer offerings. His vision for commercial growth and scientific excellence aligns perfectly with Sygnature’s culture of innovation and collaboration.”